Ramon Güimil García

Direttore Tecnico/Scientifico/R&S presso Hummingbird Diagnostics GmbH

Consumer Services

Health Technology

Profilo

Ramon Güimil García is currently working as Vice President-Research & Development at Hummingbird Diagnostics GmbH.
Prior to this, he worked as Principal at The European Molecular Biology Laboratory and Nucleic Acid Synthesis Group.

Posizioni attive di Ramon Güimil García

Società	Posizione	Inizio
Hummingbird Diagnostics GmbH Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation.	Direttore Tecnico/Scientifico/R&S	30/11/2009

Tutte le posizioni attive di Ramon Güimil García

Precedenti posizioni note di Ramon Güimil García

Società	Posizione	Fine
The European Molecular Biology Laboratory	Corporate Officer/Principal	-
Nucleic Acid Synthesis Group	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Ramon Güimil García

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ramon Güimil García

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Hummingbird Diagnostics GmbH Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation.	Health Technology
Nucleic Acid Synthesis Group